MNX1 and esophageal squamous cell carcinoma: Esophageal squamous cell carcinoma (ESCC) is the most prevalent subtype of ESCA and carries a poor prognosis, with China representing approximately half of the newly diagnosed cases.[39] In recent years, ICB‐based immunotherapy has shown a favorable effect on patients with ESCA.[40] Therefore, to confirm the association of MNX1 with cancer immunity, we silenced MNX1 expression in ESCC cell line KYSE150, which had relative high expression of MNX1 (Figure 6c,d), by transfection of MNX1‐specific small interfering RNAs (siRNAs) (Figure S1c,d in Supporting Information).